10-Q: Palisade Bio Reports Q2 Loss, Positive PALI-2108 Data

Palisade Bio announced a reduced net loss in Q2 2025, positive Phase 1 clinical trial results for PALI-2108, and a recent $3.9 million warrant exercise, but faces ongoing going concern doubts and Nasdaq compliance monitoring.

Summary

• Net loss for the three months ended June 30, 2025, decreased to $2.78 million from $4.08 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, decreased to $5.01 million from $7.61 million in the same period of 2024.
• Research and development expenses decreased by 36% to $1.68 million in Q2 2025 and 46% to $2.63 million in H1 2025, primarily due to a $1.9 million decrease in preclinical joint development expenses with Giiant.
• General and administrative expenses decreased by 26% to $1.17 million in Q2 2025 and 17% to $2.53 million in H1 2025.
• Cash and cash equivalents stood at $5.42 million as of June 30, 2025, down from $9.82 million at December 31, 2024.
• The company completed dosing for all planned cohorts of its Phase 1 clinical study of PALI-2108, including 89 healthy volunteers and 5 ulcerative colitis (UC) patients.
• Positive results from the SAD, MAD, FE, and UC cohorts of the PALI-2108 Phase 1 study were announced on May 27, 2025, and August 7, 2025, meeting primary endpoints of safety, tolerability, and pharmacokinetics.
• A warrant inducement transaction closed on July 25, 2025, generating gross cash proceeds of approximately $3.9 million.
• The company has an accumulated deficit of $141.0 million as of June 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date.
• The company received a Nasdaq notice on April 30, 2025, for non-compliance with the $1.00 minimum bid price rule, with a compliance period until October 27, 2025. Nasdaq is continuing to monitor the stock price despite a recent 10-day compliance period.

Sentiment

Score: 6

Explanation: While the company reported positive clinical trial results for its lead candidate and reduced net losses, which are significant positives for a clinical-stage biotech, the persistent "going concern" warning, short cash runway, and ongoing material weakness in internal controls temper the overall sentiment. The recent capital raise provides some immediate relief but highlights the continuous need for funding.

Positives

• Reduced net loss for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved financial efficiency.
• Significant decrease in research and development expenses, primarily due to the shift from preclinical joint development to assuming full control of PALI-2108 clinical trials.
• Positive Phase 1 clinical trial results for PALI-2108, meeting primary endpoints of safety, tolerability, and pharmacokinetics in both healthy volunteers and UC patients.
• Successful warrant inducement transaction in July 2025, raising approximately $3.9 million in gross cash proceeds, providing additional liquidity.
• The company plans to initiate an additional exploratory Phase 1b cohort for PALI-2108 in fibrostenotic Crohn's disease (FSCD) and subsequently Phase 2 clinical programs for FSCD and moderate to severe UC.
• The company's lead product candidate, PALI-2108, targets a significant market (IBD, including FSCD and UC) with a precision medicine approach.

Negatives

• Substantial doubt about the company's ability to continue as a going concern for the next year due to insufficient cash to fund anticipated operations beyond Q1 2026 without additional financing.
• Significant accumulated deficit of $141.0 million as of June 30, 2025.
• Cash and cash equivalents decreased by approximately 45% from December 31, 2024, to June 30, 2025.
• Ongoing material weakness in internal controls over financial reporting, specifically a lack of controls in the financial closing and reporting process, segregation of duties, and formalized procedures.
• Received a Nasdaq notice on April 30, 2025, for non-compliance with the $1.00 minimum bid price rule, indicating potential delisting risk if compliance is not regained by October 27, 2025, or the extended period.
• The company's corporate office lease expires on August 31, 2025, and they will not exercise the renewal option, indicating a potential change in physical presence or operational structure.
• Alto Neuroscience's Phase 2b study of ALTO-100 (NSI-189) in Major Depressive Disorder (MDD) did not meet its primary endpoint, potentially impacting future milestone payments from this licensed asset.

Risks

• Business depends on successful clinical development, regulatory approval, and commercialization of therapeutic compounds, especially PALI-2108.
• Substantial risks in drug development, with no guarantee of successful development or commercialization of any product candidate.
• Dependence on the Giiant License Agreement for PALI-2108 patents; termination or non-compliance could harm the business.
• Data from Canadian clinical trials may not be accepted by the U.S. FDA or other foreign regulatory authorities.
• Difficulty enrolling patients in clinical trials could cause delays or prevent completion.
• Operations and PALI-2108 development require substantially more capital than currently available, with no guarantee of securing additional funding on acceptable terms.
• PALI-2108 may cause undesirable side effects or have unexpected properties, delaying or preventing regulatory approval, limiting commercial profile, or resulting in post-approval regulatory action.
• No assurance that product candidates will obtain regulatory approval.
• Clinical studies of PALI-2108 may not yield successful results, leading to discontinuation of development.
• Clinical trials may take longer than estimated or may not be completed at all.
• Even if approved, future regulatory reviews or inspections could lead to suspension, withdrawal, facility closure, or substantial fines.
• Successful commercialization depends on adequate reimbursement levels and pricing policies from government authorities and health insurers.
• Potential product liability exposure could result in substantial costs and liabilities, limiting commercialization.
• Even if approved, a product candidate may fail to achieve broad physician and patient adoption.
• Limited operating history and no revenues from product sales, making it difficult to evaluate business success and future viability.
• Business model assumes revenue from marketing or out-licensing, but PALI-2108 is in early clinical development with limited history.
• May choose to discontinue development or commercialization of any product candidates at any time.
• Inability to successfully in-license, acquire, develop, and market additional product candidates could impair business growth.
• Changes in funding for the FDA and other government agencies could hinder their ability to perform normal business functions, negatively impacting the business.
• Reliance on third-party Contract Research Organizations (CROs) and other third parties to conduct clinical trials; failure to meet requirements could prevent regulatory approval or commercialization.
• Dependence on two qualified suppliers for the active pharmaceutical ingredient (API) of PALI-2108; insufficient availability or inability to supply on commercially reasonable terms could adversely impact the business.
• Reliance on collaborations with third parties for successful development and commercialization.
• Reliance on third-party contractors to supply, manufacture, and distribute clinical drug supplies.
• Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements.
• Inability to obtain, maintain, or enforce global patent rights or other intellectual property rights of sufficient breadth to prevent third-party competition.
• Failure to comply with intellectual property license agreements could lead to loss of license rights.
• Subject to patent infringement claims, resulting in substantial costs and liabilities.
• Subject to claims that officers, directors, employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets of former employers.
• Common stock could be delisted from the Nasdaq Stock Market if compliance with listing standards is not maintained.
• Future sales of substantial amounts of common stock could adversely affect the market price.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate financial statements.
• Board has broad discretion to issue additional securities, which might dilute net tangible book value per share for existing stockholders.
• Business could be adversely affected by health pandemics or epidemics, global economic conditions, and inadequate funding for government agencies.
• Information systems or data, or those of third parties, being compromised could lead to adverse consequences.

Future Outlook

The company plans to initiate an additional safety, tolerability, and PK/PD exploratory Phase 1b cohort for PALI-2108 in fibrostenotic Crohn's disease (FSCD) while completing longer-term chronic safety and toxicology studies. This will be followed by the initiation of Phase 2 clinical programs to assess PALI-2108's efficacy, safety, and tolerability in patients with FSCD and moderate to severe ulcerative colitis. The company anticipates submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and commencing clinical trials of PALI-2108 in the U.S. during the first half of 2026. The company expects to continue incurring losses and will require additional financing prior to or in the first quarter of 2026 to fund its anticipated level of operations.

Management Comments

• Based on our current working capital, anticipated operating expenses, and anticipated net operating losses, there is substantial doubt about our ability to continue as a going concern for a period of one year following the date that these condensed consolidated financial statements are issued.
• We plan to continue to fund our operations through our cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements.
• We intend to use the net proceeds from the warrant inducement transaction for working capital and general corporate purposes, including the development of PALI-2108 for the treatment of FSCD and UC.
• Our management, with the participation of our Chief Executive Officer, who is also our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2025. Based upon the evaluation, our Chief Executive Officer concluded that, as of June 30, 2025, our disclosure controls and procedures were not effective at a reasonable assurance level as a result of the material weakness that existed in our internal control over financial reporting.
• Our management, including our Chief Executive Officer, has concluded that, notwithstanding the identified material weakness in our internal control over financial reporting, the condensed consolidated financial statements in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.

Industry Context

Palisade Bio operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically focusing on autoimmune, inflammatory, and fibrotic diseases, with a lead candidate PALI-2108 targeting Inflammatory Bowel Disease (IBD). The company's precision medicine approach, aiming to identify PDE4-related biomarkers for patient selection, aligns with a broader industry trend towards personalized medicine to improve treatment efficacy and reduce trial costs. The positive Phase 1 results for PALI-2108 are a critical step in drug development, but the company faces significant financial hurdles common to clinical-stage biotechs, including substantial operating losses and the need for continuous capital raises. The failure of Alto Neuroscience's ALTO-100 (NSI-189) in MDD highlights the high risk of clinical development, even for licensed assets. The company's reliance on third-party CROs and CMOs is standard in the industry but introduces supply chain and compliance risks.

Comparison to Industry Standards

• Clinical Trial Progress: The successful completion of Phase 1 for PALI-2108 and meeting primary endpoints of safety, tolerability, and PK is a standard positive milestone for a clinical-stage biopharma company. For example, similar early-stage companies like Finch Therapeutics (developing microbiome therapies for GI diseases) or Prometheus Biosciences (acquired by Merck, focused on IBD) also progressed through Phase 1/2 trials, with positive early data being crucial for further investment and development.
• Financial Health: The "going concern" warning and significant accumulated deficit are common for early-stage biotechs that are pre-revenue. Companies like Aclaris Therapeutics or Kura Oncology also operated with substantial losses and relied on capital raises during their clinical development phases. However, the specific cash runway into Q1 2026, even with the recent capital raise, is relatively short, indicating a more immediate need for further financing compared to some peers who might have 12-18 months of runway.
• R&D Efficiency: The decrease in R&D expenses in H1 2025 compared to H1 2024 is notable, driven by the shift from preclinical joint development to direct clinical trial costs. This suggests a transition in spending focus, which can be a positive sign of pipeline progression, but the absolute R&D spend remains substantial for a company of its size.
• Corporate Governance: The identified material weakness in internal controls over financial reporting is a significant concern, contrasting with best practices for publicly traded companies. While remediation efforts are underway, this issue can deter institutional investors who prioritize strong internal controls. Companies like Enveric Biosciences or other smaller biotechs might face similar challenges, but persistent material weaknesses are generally viewed negatively.

Corporate Governance

Related Party Transactions

• Research Collaboration and License Agreement with Giiant Pharma, Inc. (Giiant) for PALI-2108 and PALI-1908, involving contingent consideration and milestone payments.
• Co-Development and Distribution Agreement with Newsoara, a joint venture with Biolead Medical Technology Limited, for LB1148 in China, involving upfront fees, milestones, and tiered royalties.
• License agreements with the Regents of the University of California, specifically the 2015 UC License, requiring payment of a percentage of non-royalty licensing revenue received from Newsoara.
• License agreement with Alto Neuroscience for NSI-189 (ALTO-100), involving potential milestone payments up to $4.5 million and a percentage of consideration from third-party licenses/sales.
• License agreement with the Regents of the University of Michigan for NSI-532.IGF-1, where the company receives 50% of net revenues from licensing patent rights by the University of Michigan.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financings; risk of delisting from Nasdaq; potential for stock price volatility; no anticipated dividends. Positive clinical trial results could increase shareholder value, but going concern and control weaknesses are concerns.
• Employees: A 25% reduction-in-workforce (2023 RIF) was completed, impacting research and development employees. Ongoing efforts to hire additional finance, accounting, and IT employees.
• Customers/Patients: Positive Phase 1 results for PALI-2108 offer hope for future treatment options for inflammatory bowel disease patients.
• Creditors: The "going concern" warning indicates increased risk for creditors.
• Suppliers/Partners: Continued reliance on third-party CROs, CMOs, and API suppliers, with risks related to their performance and supply chain disruptions. Collaboration partners like Giiant, Newsoara, Alto Neuroscience, and University of Michigan are key to pipeline development and potential future revenue.

Next Steps

• Initiate an additional safety, tolerability, and PK/PD exploratory Phase 1b cohort for PALI-2108 in fibrostenotic Crohn's disease (FSCD).
• Complete longer-term chronic safety and toxicology studies for PALI-2108.
• Initiate Phase 2 clinical programs to assess PALI-2108's efficacy, safety, and tolerability in patients with FSCD and moderate to severe ulcerative colitis.
• Anticipate submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA).
• Commence clinical trials of PALI-2108 in the U.S. during the first half of 2026.
• Alto Neuroscience expects topline data for ALTO-100 Phase 2b study in bipolar depression in the second half of 2026.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by October 27, 2025, or during any extended compliance period.
• Continue remediation efforts to address the material weakness in internal controls over financial reporting.
• Seek additional financing through equity offerings, debt financings, third-party funding, or licensing/collaboration arrangements prior to or in the first quarter of 2026.

Key Dates

Recommendation

While Palisade Bio has achieved a significant positive milestone with successful Phase 1 clinical trial results for PALI-2108 and has reduced its net loss, the company faces substantial financial challenges, including a "going concern" warning and a short cash runway requiring immediate additional financing. The ongoing material weakness in internal controls also presents a governance risk. The recent warrant exercise provides temporary liquidity but highlights the continuous need for capital. Given the early stage of its lead asset, the high burn rate, and the inherent risks of drug development coupled with financial uncertainties, a "hold" recommendation is appropriate. Investors should monitor progress on PALI-2108's next clinical phases, the company's ability to secure further funding on favorable terms, and the remediation of internal control weaknesses before considering a stronger position.

Keywords

Biopharmaceutical, Clinical-stage, PALI-2108, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Phase 1 Clinical Trial, Drug Development, SEC Filing, 10-Q, Going Concern, Nasdaq Compliance, Warrant Exercise, Biomarker, PDE4 Inhibitor